Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Ruxolitinib and ibrutinib: the future for GvHD treatment?

Katie Gatwood • 21 Mar 2018
HOPA 2018
General Ibrutinib Ruxolitinib

At present, the standard frontline therapy of steroids for graft versus host disease (GvHD) has shown to be ineffective for many patients. Now, speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, provides an interesting update on the use of ibrutinib or ruxolitinib for the treatment GvHD. Dr Gatwood gives an insight on current studies that are investigating the use of ruxolitinib for acute and chronic GvHD, with the hope of ruxolitinib becoming FDA approved in the future.

More from Katie Gatwood

1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood • 21 Mar 2018
1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood • 21 Mar 2018

Related Videos

2:14
The influence of graft source and composition on GvHD
Mattia Algeri • 15 Apr 2024
1:49
Guidelines on the diagnosis and management of neutropenia
Carlo Dufour • 15 Apr 2024
1:51
The importance of sustainable healthcare
Shireen Kassam • 24 Apr 2024
2:20
EBMT diagnostic criteria for TMA post-alloSCT and the role of complement activation
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals